ChargePoint Technology launches single-use technology as part of powder transfer solutions portfolio
Company's hybrid solution claims superior performance compared with tradition single-use technologies.
Contained and sterile transfer solutions expert, ChargePoint Technology has announced new, single-use additions to its portfolio - the ChargePoint Single Use Passive (SUP) and ChargeBag PE-S with new HiPure ULP7 PE film.
Together, the two products form a high performance, single-use package for the contained and sterile transfer of pharmaceutical powders between manufacturing process steps or even facilities.
The ChargePoint SUP is a disposable version of the passive mating half of the ChargePoint SBV (Split Butterfly Valve) technology, which forms a complete hybrid system to ensure users can take advantage of the benefits of disposable technology without compromising performance. This also ensures the new single-use products are compatible with existing ChargePoint SBV systems in the field.
Constructed completely of FDA and USP Class VI compliant materials, the SUP is both lightweight and cost effective, delivering containment and sterility assurance performance while eliminating the time and cost associated with cleaning, maintenance and validation.
The new ChargeBag PE-S is a flexible, single-use product container for the handling, storage and transfer of bio-pharmaceutical powders.
Manufactured from HiPure ULP7, a new proprietary film, developed exclusively by ChargePoint Technology, and compliance tested to meet the demands of even the most critical aseptic processing environments, the solution enables extremely high levels of integrity with optimised purity and robustness characteristics.
Chris Eccles, CEO, ChargePoint Technology says: “As pharmaceutical manufacturing environments evolve, we will continue to push the boundaries of innovation and remain at the forefront of contained transfer advancements, responding to the challenges of today and tomorrow. We are excited to take our first steps into the realm of single-use technology as we look for new ways to deliver compliant, flexible solutions to our customers.”
He continues: “Although traditional single-use technologies claim to deliver the same level of performance as some of the more robust solutions, the reality is this is not the case over repeated operations. ChargePoint’s hybrid solution delivers repeatable performance as well as offering several advantages to pharmaceutical manufacturers. The convenience and control benefits associated with pre-validated, ready to use solutions, that are easily integrated and perform to the highest level of containment and sterility assurance, are invaluable for our customers”.
In line with the next generation of transfer solutions, ChargePoint Technology is also introducing its latest update of the ChargePoint SBV system, Series 3. Featuring a new and improved locking mechanism with intuitive mechanical interlocks the system is operator friendly and reduces risk of part wear. On automatic versions, quick release actuators and sensor sockets ensure fast set up and changeover while improved access to the main disc seal makes maintenance steps more convenient than ever before.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...